J-Pharma Co., Ltd. was listed on the Tokyo Stock Exchange Growth Market on March 25, 2026.
We are pleased to make this announcement and would like to express our sincere gratitude to our shareholders and investors, as well as to all other stakeholders, for their continued support and patronage, which have made this milestone possible.

At J-Pharma, we focus on LAT1 (L-type Amino Acid Transporter 1), one of the SLC transporters, and are committed to delivering new therapeutic options for medical needs in areas such as cancer and autoimmune diseases, where existing treatments do not sufficiently address patient needs.

Bringing a new medicine to patients requires a long development process, numerous challenges, and the integration of diverse expertise both within and outside the Company. By sincerely engaging with the fundamentals of drug discovery, we are advancing our research and development with the mission of delivering meaningful and valuable therapies that address unmet medical needs.

For diseases where existing therapies have reached their limits, there is a need to explore entirely new classes of medicines—that is, first-in-class therapies. For nearly 30 years, I have devoted myself to pursuing this dream of innovative drug discovery and have steadily built experience and achievements in this field.

Throughout this journey, I have consistently held onto the concept of developing "cancer therapy as warm as the sun." Rather than simply attacking cancer cells, our goal is to support patients' daily lives by creating treatments that can be used over the long term and help make everyday living more manageable. This represents the pursuit of a new therapeutic approach that differs fundamentally from conventional "north-wind-like chemotherapy."

Our LAT1 inhibitor, nanvuranlat, currently under development, has achieved its primary endpoint in a domestic Phase II clinical trial for biliary tract cancer and has received international recognition through presentations at academic conferences and other forums. With its favorable safety profile, we believe that this drug has the potential to be administered over the long term, including in elderly cancer patients, and to become a novel therapy that enables patients to Feel Better & Live Longer.

I am fully committed to dedicating all of my accumulated global development experience and expertise to delivering this medicine as a source of hope to patients who need it. Beyond biliary tract cancer, we see significant future opportunities for further expansion, and we will continue to bring our technology to patients around the world as pharmaceutical products, striving to achieve sustainable and transformative growth as a Japan-origin global drug discovery venture.

As a publicly listed company, we are mindful of our social responsibilities and will continue to engage in constructive dialogue with our shareholders and investors by further enhancing the effectiveness of our corporate governance and ensuring transparent information disclosure. With respect to research and development investment, we will rigorously implement disciplined management that carefully balances progress and risk management while maintaining a strong focus on capital efficiency, thereby striving to achieve sustainable growth in corporate value.

Going forward, under a framework of sound governance and transparent disclosure, we will steadily advance our research and development and strive to achieve both enhanced corporate value and meaningful contributions to healthcare. We sincerely appreciate your continued understanding and support.

March 25, 2026
Masuhiro Yoshitake
President & Representative Director
J-Pharma Co., Ltd.